- Bladder Cancer
- Brain Cancer
- Breast Cancer
- Colorectal Cancer
- Gastrointestinal Cancers
- Gynecological Cancers
- Haematological Malignancies
- Lung Cancer
- Prostate Cancer
- Renal Cancer
- Supportive Care
Webcasts
Key Trials
- A New Urine DNA mutation Detection Test Offers Promise in Detecting Recurrence in Non-Muscle-Invasive Bladder Cancer
- Efficacy and Safety of Intravesical Bacillus Calmette-Guérin Immunotherapy in Patients with Non-Muscle-Invasive Bladder Cancer Presenting with Asymptomatic Bacteriuria (ABU)
- Recent Therapeutic Updates on Non-Muscle Invasive Bladder Cancer (NMIBC)
- Transurethral Endoscopic Thulium Laser En Bloc Resection of Non-Muscle-Invasive Bladder Cancer Avoids Repeat Transurethral Resection
- Narrow Band Imaging Might be a Promising Diagnostic Intervention in Non-Muscle Invasive Bladder Cancer
- Survival Outcomes with Extended and Limited Lymph Node Dissection in Bladder Cancer Patients undergoing Radical Cystectomy
- BCG Therapy Significantly Reduced Recurrence and Progression in High Risk Non-Muscle-Invasive Bladder Cancer
- Significant Reduction in the Risk of Treatment Failure with Bacillus Calmette-Guerin Therapy Compared to Chemotherapy in Carcinoma in Situ of the Bladder
.jpg)
Conference Proceedings
Guidelines
- NCCN: Clinical Practice Guidelines in Oncology (2021)
- ESMO: Bladder Cancer Treatment Recommendations (2020)
- Cancer Guideline Resource Centre
- ISCCM: End of Life Care Policy for the Dying: Consensus Position Statement of Indian Association of Palliative Care (2014)
- International Bladder Cancer Group - Defining and Treating the Spectrum of Intermediate-Risk NMIBC (2012-2013)
Our Publications
Patient Education
Clinical Tools
Webcasts
Our Publications
Key Trials
- Lapatinib plus Capecitabine versus Capecitabine Alone in Women with Progressive HER2-positive in Locally Advanced or Metastatic Breast Cancer
- Clinical Efficacy of Lapatinib Combined with Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer
- Efficacy and Safety of Trastuzumab and Lapatinib Combined Chemotherapy in Real-World Setting HER2+ MBC
- Eri-001 Trial: Eribulin, An Effective and Safe Therapeutic Option in Heavily Pre-treated patients with Advanced Breast Cancer Treatment
- Outcomes of Treatment with Eribulin for Metastatic Triple-negative Breast Cancer in Real-World Clinical Setting
- ALTERNATIVE Trial: LAP+ TRAS+ AI as Sparing Alternative Regimen for Metastatic Breast Cancer
- LANDSCAPE TRIAL: Lapatinib in Combination with Capecitabine Active As First-line Treatment of Brain Metastases from HER2-positive Breast Cancer
- Risk Predictors of Brain Metastases Development in Patients with HER2- Positive Breast Cancer
- GeparQuinto Trial: Lapatinib versus Trastuzumab in Combination with Chemotherapy for Treatment of HER2-positive Primary Breast Cancer
- SWISH Trial: Dexamethasone Oral Solution Four Times a Day, Keeps Stomatitis Away
- Exemestane Plus Ovarian Suppression Demonstrates Sustained Higher Rates of Disease Free Survival in Premenopausal Women with Breast Cancer
- CREATE-X Trial: Adjuvant Capecitabine Safe and Effective in HER2-Negative Breast Cancer Patients
- The CBC Trial: Sustained Reduction in Mortality with Two-year Adjuvant Tamoxifen in High-risk Breast Cancer Patients
- Gemcitabine plus Paclitaxel: A Favourable Option for Patients with Metastatic Breast Cancer and Prior Anthracycline Treatment
- Zoledronic Acid: An Effective, Safe and Convenient Alternative to Pamidronate for Reducing Long-Term Skeletal Morbidity in Patients with Advanced Multiple Myeloma or Breast Cancer
- Phase III Trial: Nanoparticle Albumin-Bound Paclitaxel vs. Standard Paclitaxel in Women with Metastatic Breast Cancer
Conference Proceedings
Patient Education
Guidelines
- NCCN: Clinical Practice Guidelines in Oncology (2021)
- ESO-ESMO: International Consensus Guidelines for Advanced Breast Cancer (ABC 5) (2020)
- ESMO: Guidelines for Advanced Breast Cancer (2020)
- ASCO: Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer (2020)
- Cancer Guideline Resource Centre
- ASBrS: Contralateral Prophylactic Mastectomy Consensus Statement (2016)
- ASCO/ASTRO/SSO: Use of Postmastectomy Radiotherapy (2016)
- ACS: Breast Cancer Screening for Women at Average Risk (2015)
- ISCCM: End of Life Care Policy for the Dying: Consensus Position Statement of Indian Association of Palliative Care (2014)
Webcasts
Our Publications
Key Trials
- Efficacy of 6 Months of Capecitabine vs. 12 Months as Adjuvant Chemotherapy for Patients with Stage III CRC
- Efficacy and Safety of mXELIRI Regimen versus Standard FOLFIRI Regimen, W or W/o Bevacizumab as a Second-line Therapy for Metastatic Colorectal Cancer
- COLOR II Trial: Laparoscopic Surgery as Safe and Effective as Open Surgery in Rectal Cancer
Patient Education
Guidelines
- ASTRO : Guideline on Radiation Therapy for Rectal Cancer (2021)
- NCCN: Clinical Practice Guidelines in Oncology (2021)
- ESMO: Clinical Practice Guidelines - Localized Colon Cancer (2020)
- Cancer Guideline Resource Centre
- USPSTF: Use of Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancers (2016)
- ISCCM: End of Life Care Policy for the Dying: Consensus Position Statement of Indian Association of Palliative Care (2014)
Our Publications
Patient Education
Clinical Tools
Guidelines
- ESMO : Updated Treatment Recommendations for Hepatocellular Carcinoma (HCC) (2021)
- NCCN: Clinical Practice Guidelines in Oncology (2021)
- ASCO: Systemic Therapy for Advanced Hepatocellular Carcinoma (2020)
- Cancer Guideline Resource Centre
- CAP/ASCP/ASCO: HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma (2016)
- ISCCM: End of Life Care Policy for the Dying: Consensus Position Statement of Indian Association of Palliative Care (2014)
Our Publications
Guidelines
- NCCN: Clinical Practice Guidelines in Oncology (2021)
- ACS: Cervical Cancer Screening for Individuals at Average Risk (2020)
- Cancer Guideline Resource Centre
- ASCO: Secondary Prevention of Cervical Cancer (2016)
- ASCO/SGO: Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer (2016)
- ASCO: Management and Care of Women with Invasive Cervical Cancer (2016)
- ISCCM: End of Life Care Policy for the Dying: Consensus Position Statement of Indian Association of Palliative Care (2014)
Webcasts
Expert's Viewpoint
- Webinar Snippet: What Is The Evidence With Dasatinib In The Front-Line Setting In Patients With CML?
- Webinar Snippet: What Are The Key Recommendations Of The 2020 ELN Guidelines For Treatment Of CML?
- Webinar Snippet: Can TKI Therapy Be Stopped In CML?
- Webinar Snippet: What Are The Key Milestones In The Journey Of Dasatinib?
- Webinar Snippet: What Are The Successes And Failures With Imatinib In CML?
- Webinar Snippet: What Is The History Of CML Therapy?
- Webinar Snippet: What Are The Factors Determining Prognosis In CML?
- Webinar Snippet: What Is The Differential Diagnosis Of CML?
Our Publications
Key Trials
- DASSION Trial: 2 -Year Efficacy and Safety of Dasatinib versus Imatinib in Treatment of Newly Diagnosed CML-CP
- DASISION Study: Efficacy and Safety of Dasatinib versus Imatinib for the First-Line Treatment of Chronic-phase CML
- DASISION Trial: 5-Year Efficacy and Safety of Dasatinib Versus Imatinib in Patients with Newly Diagnosed Chronic Phase CML
- STRATUS Trial: POM+ LoDEX, Safe and Effective in Heavily Pretreated RRMM Patient
- Pomalidomide plus Low-dose Dexamethasone More Effective in Patients with Relapsed and Refractory Multiple Myeloma Compared to High-dose Dexamethasone Alone
- Pomalidomide + Dexamethasone: Safe and Effective in RRMM Patients with Moderate Renal Impairment-II
- Pomalidomide + Dexamethasone-Efficacious and Tolerable in RRMM Patients Regardless of Age
- Pomalidomide + Dexamethasone: Safe and Effective in RRMM Patients with Moderate Renal Impairment-I
- Pomalidomide + Dexamethasone - Efficacious in RRMM Patients Regardless of Cytogenetic Risk Profile
- Impact of Consolidation Therapy Preceding the Maintenance Therapy in Newly Diagnosed, Transplant Eligible Multiple Myeloma Patients
- Imatinib - A Jewel in the Crown as First-line Therapy for Chronic Myeloid Leukemia: Insights from an Indian Study
- Safety and Efficacy of Bendamustine-Rituximab Combination as a Frontline Therapy for the Treatment of Patients with Chronic Lymphocytic Leukemia
- Long-term Efficacy and Safety of Imatinib in Chronic Myeloid Leukemia
Conference Proceedings
Patient Education
Guidelines
- EHA-ESMO : Multiple Myeloma: Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up (2021)
- NCCN: Clinical Practice Guidelines in Oncology (2021)
- ESMO: Newly Diagnosed and Relapsed Follicular Lymphoma: Guidelines for Diagnosis, Treatment and Follow-up (2020)
- NICE: Diagnosis and Management of Non-Hodgkin’s Lymphoma (2016)
Webcasts
- How My Treatment for Lung Cancer Changed in Last 1-Year Post WCLC, ESMO and ASCO-Latest Update
- PURVIEW - Lung Cancer
- Personalized Therapy for Advance NSCLC and Recent Changes in the Treatment Paradigm
- Lung Cancer: Changing Concepts that Pulmonologists Should Know
- Bronchoscopy in Lung Cancer: Role & Limitations
- Lung Cancer: The Emerging Role of The Pulmonologist
Our Publications
Key Trials
- ENSURE Trial: Erlotinib versus Gemcitabine/cisplatin as First-line Treatment in EGFR mutation-positive Non-small-cell Lung Cancer Patients
- EURTAC Trial: Erlotinib versus Standard Chemotherapy as First-line Treatment in Advanced EGFR mutation-positive NSCLC Patients
- OPTIMAL Trial: Erlotinib versus Chemotherapy as First-line Treatment for Patients with Advanced EGFR Mutation-positive Non-small-cell Lung Cancer
- ElderTac Study: Erlotinib, A Potential Palliative Treatment for Elderly Patients with Advanced NSCLC
Conference Proceedings
Patient Education
Guidelines
- ESMO: Lung and Thymic Carcinoids: Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up (2021)
- NCCN: Clinical Practice Guidelines in Oncology (2021)
- Cancer Guideline Resource Centre
- ISCCM: End of Life Care Policy for the Dying: Consensus Position Statement of Indian Association of Palliative Care (2014)
Webcasts
- New Approaches Towards Treating Men with Metastatic Prostate Cancer
- Sequencing in Prostate Cancer: An Update
- Updates in the Management of Prostate Cancer
- Hormonal Therapy in Management of Prostate Cancer: The Evolving Role
- CRPC: Adapting to New Treatment Paradigms
- Managing CRPC – Current Challenges (Panel Discussion)
- Clinical Appraisal of Abiraterone Acetate in the Management of CRPC (Panel Discussion)
- Early Stage Prostate Cancer Clinical Stage T1NOMO, Gleason 3+3. How Will I Manage?
- It's Time to Abandon the Upper Limit of Normal for PSA
- Management of CRPC: Where do we Stand in 2012?
- Dutasteride for Chemoprevention: Current Status and Future Prospects
Our Publications
Key Trials
- Local Salvage Therapies in Radiation Recurrent Prostate Cancer – Are they Beneficial?
- Oncological and Functional Outcomes with High-Intensity Focused Ultrasound in the Treatment of Prostate Cancer
- Non-Inferiority of Degarelix with Goserelin in Chinese Men with Prostate Cancer
- Improved Survival Outcomes with Androgen-Receptor-Axis-Targeted Therapies in Metastatic Castration-Sensitive Prostate Cancer
- AFFIRM Trial: Enzalutamide Significantly Prolonged Survival in Men with Metastatic Castration-Resistant Prostate Cancer After Chemotherapy
- PROSPER Trial: Enzalutamide Associated with Significantly Prolonged Overall Survival than Placebo in Men with Nonmetastatic, Castration-resistant Prostate Cancer Receiving Androgen-deprivation Therapy
- Salvage Radiotherapy along with Hormone Therapy Improves Outcomes in Prostate Specific Antigen Failure after Radical Prostatectomy
- PSMA-Guided Radiotherapy Offers Promise in Men with Oligorecurrent Prostate Cancer
- No Significant Changes in Lipid and Glucose Metabolism with Degarelix and Leuprolide Treatment in Prostate Cancer
- Addition of Docetaxel to Androgen Deprivation Therapy Improves Survival Outcomes and is Cost-Effective in Metastatic Prostate Cancer
- Apalutamide Prolongs Survival in Metastatic Castration-Sensitive Prostate Cancer: Findings of TITAN Trial
- Addition of Enzalutamide to Standard First-Line Therapy Prolongs Survival in Metastatic Prostate Cancer
- Early Use of Vacuum Therapy Has an Excellent Therapeutic Effect in Men undergoing Radical Prostatectomy
- Enzalutamide and Abiraterone Improved Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer
- LATITUDE Study: Abiraterone Plus Prednisone Might Be Clinically Beneficial in Men with Metastatic Castration-Sensitive Prostate Cancer
- Antiandrogen Therapy with Daily Bicalutamide and Radiation Therapy Improves Survival in Recurrent Prostate Cancer
- COU-AA-302: Abiraterone Acetate with Prednisone is Superior to Prednisone Alone in Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer Patients
Conference Proceedings
Guidelines
- ASCO: Initial Management of Non-Castrate Advanced, Recurrent or Metastatic Prostate Cancer (2021)
- ASCO : Initial Management of Non-Castrate Advanced, Recurrent or Metastatic Prostate Cancer (2021)
- NCCN: Clinical Practice Guidelines in Oncology (2021)
- AUA-ASTRO-SUO: Advanced Prostate Cancer Guidelines: A Continued but Changing Role for the Radiation Oncologist (2020)
- AUA: Castration-Resistant Prostate Cancer (2018)
- Cancer Guideline Resource Centre
- ISCCM: End of Life Care Policy for the Dying: Consensus Position Statement of Indian Association of Palliative Care (2014)
- AUA: Best Practice Statement on PSA Testing for the Pretreatment Staging and Posttreatment Management of Prostate Cancer (2013)
- AUA: Best Practice Statement on Cryosurgery for the Treatment of Localized Prostate Cancer (2010)